EGAGenomicsIllumina HiSeq 2000;https://ega-archive.org/datasets/EGAD000010020832EGA dataset EGAD00001002083EGAColorectal carcinoma represents a heterogeneous entity, with only a fraction of the tumours responding to available therapies, requiring a better molecular understanding of the disease in precision oncology. To address this challenge, the OncoTrack consortium recruited 106 CRC patients (stages I-IV) and developed a pre-clinical platform generating a compendium of drug sensitivity data totalling >4,000 assays testing 16 clinical drugs on patient-derived in vivo and in vitro models. This large biobank of 106 tumours, 35 organoids and 59 xenografts, with extensive omics data comparing donor tumours and derived models provides a resource for advancing our understanding of CRC. Models recapitulate many of the genetic and transcriptomic features of the donors, but defined less complex molecular sub-groups because of the loss of human stroma. Linking molecular profiles with drug sensitivity patterns identifies novel biomarkers, including a signature outperforming RAS/RAF mutations in predicting sensitivity to the EGFR inhibitor cetuximab.Molecular dissection of colorectal cancer in pre-clinical models identifies biomarkers predicting sensitivity to EGFR inhibitors.Schütte Moritz M, Risch Thomas T, Abdavi-Azar Nilofar N, Boehnke Karsten K, Schumacher Dirk D, Keil Marlen M, Yildiriman Reha R, Jandrasits Christine C, Borodina Tatiana T, Amstislavskiy Vyacheslav V, Worth Catherine L CL, Schweiger Caroline C, Liebs Sandra S, Lange Martin M, Warnatz Hans-Jörg HJ, Butcher Lee M LM, Barrett James E JE, Sultan Marc M, Wierling Christoph C, Golob-Schwarzl Nicole N, Lax Sigurd S, Uranitsch Stefan S, Becker Michael M, Welte Yvonne Y, Regan Joseph Lewis JL, Silvestrov Maxine M, Kehler Inge I, Fusi Alberto A, Kessler Thomas T, Herwig Ralf R, Landegren Ulf U, Wienke Dirk D, Nilsson Mats M, Velasco Juan A JA, Garin-Chesa Pilar P, Reinhard Christoph C, Beck Stephan S, Schäfer Reinhold R, Regenbrecht Christian R A CR, Henderson David D, Lange Bodo B, Haybaeck Johannes J, Keilholz Ulrich U, Hoffmann Jens J, Lehrach Hans H, Yaspo Marie-Laure MLVasp, VASP, Data Set., DmelCG15112, ENHANCER OF ATNSI ACTIVITY, MENA, NDPP1, l(2)02029, Enb, enb, ENA, Ena, CG15112, ENA/VASPaverage, preventive measures, Omental Appendix, Controlling, preventive therapy, simple tissue., reference sample, Genomes, COLON, control, Taenia Coli, prophylaxis, Appendix, Tissue, posterior intestine, Appendices, whole genome, Omental, Omental Appendices, prevention and control, Appendix Epiploica, hindgut, Controlled, preventionDER/faint little ball, Colorectal Neoplasm, Biological Markers, Viral Marker, Colorectal Cancer, Surrogate Endpoints, D-Egf, PhrB photolyase activity, Clinical Markers, Laboratory, Clinical Marker, C-erb, Neoplasms, Elp-B1, der, Biochemical, Elp-1, mor1, Endpoint, Errb1, Tumor, photoreactivating enzyme activity, Serum, mENA, pigmented epithelium, EK2-6, autosomal dominant, Surrogate End Points, PIG61, Colorectal, colorectal cancer, Surrogate Markers, Laboratory Markers, Biological, sensitive, epidermal growth factor-activated receptor activity, AI552599, c-erbB, EGFr, Egfr, torpedo/Egfr, EGF receptor activity, 3, stratum pigmentosa retinae, TOP, NUP96, Egf-r, d-egf-r, epithelium, sensitivity, Colorectal Tumors, Biomarker, EGF-R, MOS3, deoxyribocyclobutadipyrimidine pyrimidine-lyase activity, Clinical, PRECOCIOUS, Biological Marker, pigmented retina, F23A5.3, inhibiteur, top, Colorectal Carcinomas, Torpedo/DER, Colorectal Tumor, antagonists and inhibitors., DNA cyclobutane dipyrimidine photolyase activity, flb, large intestine cancer, SUPPRESSOR OF AUXIN RESISTANCE 3, top/flb, cancer of the large intestine, allergic reaction, Immunologic Markers, Immune, Markers, inhibidor, l(2)57EFa, Viral Markers, Sensitivity, 9030024J15Rik, D-EGFR, l(2)57Ea, Immunologic Marker, somatic mutation, F23A5_3, Biologic, NISBD2, colorectal (colon or rectal) cancer, Tumors, Cancer, DER1, Elp-B1RB1, Dissections, inhibitors, PRE, Carcinoma, Viral, Elp, Surrogate Endpoint, Wa5, l(2)09261, TGF-alpha receptor activity, ERBB, dEGFR1, DEgfr, deoxyribonucleic cyclobutane dipyrimidine photolyase activity, Serum Markers, End Point, inhibitor, Biochemical Markers, Biologic Marker, CG10079, Immune Marker, torpedo/egfr, MODIFIER OF SNC1, epidermal growth factor receptor activity, retinal pigment, wa2, DmelCG10079, Marker, Surrogate End Point, deoxyribonucleic photolyase activity, Neoplasm, dipyrimidine photolyase (photosensitive), CRC, Colorectal Cancers, DER/top, retinal pigment layer, Biologic Markers, Carcinomas, antagonists, large bowel cancer, egfr, Serum Marker, RPE, HD-33, El, End Points, top/DER, photolyase activity, Surrogate, DER/EGFR, EGFR, EGfr, EgfR, susceptibility to, Colorectal Carcinoma, Endpoints, dEgfr, Specificity, DER flb, ERBB1, Cancers, Immunologic, wa-2, Laboratory Marker, Torpedo/Egfr, cancer of large bowel, Surrogate Marker, p. pigmentosa retinae, Degfr, phr A photolyase activity, Egf, colon cancer, EFG-R, DNA-photoreactivating enzyme, Specificity and Sensitivity, Biochemical Marker, Errp, Erbb, DEGFR, l(2)57DEFa, l(2)05351, Der, DER, cancer of the large bowel, dEGFR, deoxyribonucleate pyrimidine dimer lyase (photosensitive), transforming growth factor-alpha receptor activity, cancer of large intestine, DmHD-33, DER/torpedo, HER1, Immune MarkersColorectal Neoplasm, RAS, Ras, l(1)G0098, Surrogate Endpoints, PhrB photolyase activity, Product, Laboratory, acetylglucosaminyltransferase-like protein, Addresses, Elp-B1, der, Elp-1, Errb1, raf, TRANSPL HETEROL, Tumor, Ras-1, PIG61, Mutations, ras, c-ras2, MAb C225, DmelCG12298, Biological, epidermal growth factor-activated receptor activity, 3, SCRAMBLED, NUP96, myd, epithelium, Atf4, Colorectal Tumors, 929, DmelCG8669, like-acetylglucosaminyltransferase, Draf-1, Tissue, F20O9.210, Mbp-1, Colorectal Carcinomas, CRUCIFERIN C, Colorectal Tumor, D-raf1, flb, SUPPRESSOR OF AUXIN RESISTANCE 3, allergic reaction, Specimen Bank, Xenotransplantations, Organoid, medicine, 9030024J15Rik, Homo sapiens disease, Tissue Donor, colorectal (colon or rectal) cancer, CG1799, Tumors, Transplant Donor, Viral, Ras2, RAS2, Elp, l(1)phl, Ras1, RAS1, DEgfr, potp, Transplant, familial, STRUBBELIG, Semen Donors, Test, Biological Substance, torpedo/egfr, Specimen Banks, Marker, mKIAA0609, dRas85D, dipyrimidine photolyase (photosensitive), Donors, Colorectal Cancers, l(2)crc, Biobanks, ras1, ras2, BcDNA:RE36103, Carcinomas, fg, egfr, Xenotransplantation, Biological Substance Banks, l(1)pole hole, HD-33, El, End Points, DER/EGFR, EGFR, EGfr, EgfR, Biological Specimen Bank, Hras-1, DER flb, Dm Ras1, Immunologic, Laboratory Marker, l(1)polehole, Torpedo/Egfr, D-raf, cancer of large bowel, human, Semen Donor, Degfr, ATF-4, MDC1D, RasI, enr, antagonists and inhibitors, DEGFR, l(2)05351, cancer of the large bowel, Afr-1, EG:BACH48C10.3, ATF4/crc, Organ Donors, Harvey-ras, Hras1, Biorepositories, Colorectal Cancer, Clr, D-Egf, In Vitro as Topic, Clinical Marker, Neoplasms, dRas, CG1167, H-ras, DRaf, DRAS1, DRas2, IMPDH, mENA, AFR1, EK2-6, Afr1, LARGE1, draf, LD06825, Human, Dras2, In Vitro Testing, Dras1, colorectal cancer, IMC-C225, D-Ras, sensitive, EGFr, Egfr, disease or disorder, Kras-2, torpedo/Egfr, anon-EST:Liang-2.17, TOP, anon-EST:Liang-2.11, IMPdH, Ha-ras, Technique, Man, In Vitro Tests, D-RAF, D-Raf, Dras, ras 1, In, mKIAA0854, Clinical, MDDGB6, raspberry/impd, mei-1794, F23A5.3, top, Phl, Ras[V12], EK3-4, Transplant Donors, cancer of the large intestine, DRas, DRas85D/Ras, Dmras64B, drugs, Draf, Ovum Donor, constitutitional genetic, Heterologous, Biologic, Cancer, Pharmaceuticals, Organ, Elp-B1RB1, inhibitors, Products, TGF-alpha receptor activity, ERBB, dEGFR1, raf-1, Serum Markers, disorders, eth, D-ras-1, Immune Marker, E(faf), DmelCG1167, In Vitro Test, XENOTRANSPL, Surrogate End Point, Neoplasm, S35097, condition, Donor, Crc, CRC, DER/top, Vitro Testing, Biologic Markers, RAS85D, RPE, Dmras85D, Pharmaceutic Preparations, l(1)9Eb, Surrogate, Colorectal Carcinoma, Dub, Endpoints, Specificity, crc, Cancers, CRIB, Understanding, wa-2, p. pigmentosa retinae, l(1)polehole/draf, crt, colon cancer, like-glycosyltransferase, Biological Specimen, Erbb, In Vitro Technique, Substance Bank, Erbitux, deoxyribonucleate pyrimidine dimer lyase (photosensitive), ph, Pharmaceutical Products, hereditary, stromal connective tissue, Immune Markers, DER/faint little ball, Ras1/RAs85D, Biological Markers, Viral Marker, Heterograft, Feature, Mbp1, Biochemical, Endpoint, c-rasHa, E(sev)3C, Serum, F20O9_210, pigmented epithelium, CG11485, SUB, Readability, Techniques, Laboratory Markers, diseases, AI552599, Pharmaceutical Product, diseases and disorders, d-egf-r, KIF20A, D-Ras1, Bank, human disease, Man (Taxonomy), RTK, l(1)G0436, pigmented retina, ras85B, ras85D, Banks, DNA cyclobutane dipyrimidine photolyase activity, large intestine cancer, genetic, Immune, D-ras-2, Markers, Pharmaceutical, Viral Markers, Therapies, D-EGFR, somatic mutation, NISBD2, DER1, Therapy, PRE, Carcinoma, l(3)s1747, Surrogate Endpoint, Wa5, l(2)09261, gyltl1b-b, Ki-ras, deoxyribonucleic cyclobutane dipyrimidine photolyase activity, Modern, KIAA0854, Biochemical Markers, Biologic Marker, CG10079, ZHX2, retinal pigment, wa2, MDDGA6, Diseases, p21[Ras1], Pharmaceutic, dRas1, dRAS1, KIAA0609, DRaf1, retinal pigment layer, Heterologous Transplantations, Dras85D, anon-EST:fe3D7, acetylglucosaminyltransferase-like 1A, ras-2, l(1)G0475, Xenograft, cruciferin 3, l(1)G0351, gyltl1b, LD02673, In Vitro, Transplantation, DmelCG1799, c-Ha-ras, Draf1, C225, Tests, D-ras1, l(1)G0238, susceptibility to, D-ras2, raf1, dEgfr, mdc1d, C-ras1, Xenografts, Dras64B, Features, LARGE_HUMAN, Treatments, C-ras2, l(3)06677, l(1)G0002, disease, phr A photolyase activity, l(1)G0482, Semen, Health, DNA-photoreactivating enzyme, Patient, Specificity and Sensitivity, Biochemical Marker, c-H-ras, l(1)G0127, l(2)57DEFa, CG8669, C110, dEGFR, inherited genetic, cancer of large intestine, DmHD-33, mKIAA0147, Ovum, Ovum Donors, AI118201, rafl, AT1G11140, other disease, human being, Testings, Health Resource, RasV12, Clinical Markers, C-erb, Kras2, mor1, DmelCG9375, photoreactivating enzyme activity, Transplantations, autosomal dominant, froggy, Gyltl1a, heterologous transplantation, CG12298, Surrogate End Points, l(1)G0388, Colorectal, Surrogate Markers, Biorepository, dATF-4, Homo sapiens, c-erbB, EGF receptor activity, stratum pigmentosa retinae, Egf-r, clone 2.11, IMC C225., l(1)G0380, Resources, sensitivity, Raf1, Drugs, p21B, Biomarker, EGF-R, MOS3, deoxyribocyclobutadipyrimidine pyrimidine-lyase activity, dras1, Dm-ras-64B, PRECOCIOUS, DmelCG2845, clone 2.17, Biological Marker, Scrb1, CG9429, Heterografts, inhibiteur, Torpedo/DER, LARGE, Ire1, l(1)G0391, top/flb, non-neoplastic, Substance Banks, BPFD#36, Ras 85D, Immunologic Markers, inhibidor, l(1)raf, l(2)57EFa, vartul, Clients, disorder, Sensitivity, SRF9, l(2)57Ea, Characteristics, Preparation, ras-l, Immunologic Marker, F23A5_3, l(1)G0056, CG9375, SCRIB1, End Point, inhibitor, K-ras, l(1)2Fe, medical condition, Medications, Client, Testing, STRUBBELIG-RECEPTOR FAMILY 9, MODIFIER OF SNC1, fs(3)05703, Raf/phl, Characteristic, Resource, epidermal growth factor receptor activity, DmelCG10079, EP(X)1093, deoxyribonucleic photolyase activity, In Vitro Testings, AI929937, antagonists, large bowel cancer, Serum Marker, Organ Donor, top/DER, photolyase activity, HETEROL TRANSPL, patient, ERBB1, l(1)ph, Biological Substance Bank, Su(tor)3-2, Surrogate Marker, 11-29, Drug, DmelCG9429, Preparations, Egf, EFG-R, Therapeutic, Errp, Modern Man, Der, DER, Treatment, transforming growth factor-alpha receptor activity, Biobank, Raf, RAF, T19D16.8, SCM, DER/torpedo, HER1, Pharmaceutical Preparation, glycosyltransferase-like protein LARGE1, CG2845falseena-DATASET-MPIMG-04-05-2016-11:07:45:674-105 - samplesWhole-genome sequencing on Illumina HiSeq2000/2500 of normal colon control tissue2017-07-26 15:39:29EGAD00001002083960628186126EGAC00001000469EGAS00001001752